Inhaltsbereich
| 72 Einträge | 1, 2, 3, 4 › » |
Seite 1 / 4
 Druckansicht
|
| Fibroblast growth factor receptor 3 isoforms: novel therapeutic targets for hepatocellular carcinoma? |
| Paur J, Nika L, Maier C, Moscu-Gregor A, Kostka J, Huber D, Mohr T, Heffeter P, Schrottmaier WC, Kappel S, Kandioler D, Holzmann K, Marian B, Berger W, Grusch M, Grasl-Kraupp B |
| Hepatology (Baltimore, Md.). 2015 Aug 1. doi: 10.1002/hep.28023 |
| PMID: 26235436 |
| Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. |
| Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, Poli V, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V, Eferl R |
| Oncoimmunology. 2015 Jan 22. doi: 10.1080/2162402X.2014.998529. pii: 998529. pmc: PMC4485776 |
| PMID: 26137415 |
| Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. |
| Mathieu V, Chantôme A, Lefranc F, Cimmino A, Miklos W, Paulitschke V, Mohr T, Maddau L, Kornienko A, Berger W, Vandier C, Evidente A, Delpire E, Kiss R |
| Cellular and molecular life sciences : CMLS. 2015 Apr 14. doi: 10.1007/s00018-015-1902-6. pii: 10.1007/s00018-015-1902-6 |
| PMID: 25868554 |
| Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. |
| Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E |
| Nature communications. 2015 Mar 3. pii: ncomms7285. doi: 10.1038/ncomms7285. pmc: PMC4366489 |
| PMID: 25734337 |
| Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. |
| Spiegl-Kreinecker S, Lötsch D, Ghanim B, Pirker C, Mohr T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J, Berger W |
| Neuro-oncology. 2015 Feb 13. pii: nov010. doi: 10.1093/neuonc/nov010 |
| PMID: 25681309 |
| The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. |
| Dornetshuber-Fleiss R, Heilos D, Mohr T, Richter L, Süssmuth RD, Zlesak M, Novicky A, Heffeter P, Lemmens-Gruber R, Berger W |
| Biochemical pharmacology. 2014 Dec 31. pii: S0006-2952(14)00727-8. doi: 10.1016/j.bcp.2014.12.013. pmc: PMC4379350. mid: EMS62789 |
| PMID: 25557295 |
| Proteome profiling of keratinocytes transforming to malignancy. |
| Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R |
| Electrophoresis. 2015 Jan 28. doi: 10.1002/elps.201400309 |
| PMID: 25395074 |
| Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. |
| Gauglhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, Pirker C, Mohr T, Heinzle C, Holzmann K, Marian B, Schulte-Hermann R, Berger W, Krupitza G, Grusch M, Grasl-Kraupp B |
| Carcinogenesis. 2014 Jul 16. pii: bgu151. doi: 10.1093/carcin/bgu151 |
| PMID: 25031272 |
| The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. |
| Heffeter P, Atil B, Kryeziu K, Groza D, Koellensperger G, Körner W, Jungwirth U, Mohr T, Keppler BK, Berger W |
| European journal of cancer (Oxford, England : 1990). 2013 Jun 18. pii: S0959-8049(13)00426-7. doi: 10.1016/j.ejca.2013.05.018. pmc: PMC3807657 |
| PMID: 23790465 |
| Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. |
| Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C |
| Journal of proteome research. 2013 Jun 19. doi: 10.1021/pr400124w. pmc: PMC3733130 |
| PMID: 23713901 |
| Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. |
| Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B |
| Hepatology (Baltimore, Md.). 2011 Feb 11. doi: 10.1002/hep.24099 |
| PMID: 21319186 |
| Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. |
| Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stättner S, Mohr T, Zwickl H, Paulitschke V, Baron DM, Trittner W, Kubicek M, Bayer E, Slany A, Gerner C |
| Electrophoresis. 2009 Jul 14. doi: 10.1002/elps.200900072 |
| PMID: 19582709 |
| Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. |
| Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C |
| Journal of proteome research. 2009 Jun 3. doi: 10.1021/pr8010827. pii: 10.1021/pr8010827 |
| PMID: 19222175 |
| FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities. |
| Allerstorfer S, Sonvilla G, Fischer H, Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C, Buchroithner J, Pichler J, Silye R, Mohr T, Holzmann K, Grasl-Kraupp B, Marian B, Grusch M, Fischer J, Micksche M, Berger W |
| Oncogene. 2008 Mar 24. pii: onc200861. doi: 10.1038/onc.2008.61. pmc: PMC2879862. mid: UKMS30927 |
| PMID: 18362893 |
| Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. |
| Kryeziu K, Pirker C, Englinger B, van Schoonhoven S, Spitzwieser M, Mohr T, Körner W, Weinmüllner R, Tav K, Grillari J, Cichna-Markl M, Berger W, Heffeter P |
| Oncotarget. 2016 Mar 28. pii: 8415. doi: 10.18632/oncotarget.8415 |
| PMID: 27036042 |
| Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. |
| Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W |
| Oncotarget. 2016 Jun 29. pii: 10324. doi: 10.18632/oncotarget.10324 |
| PMID: 27367030 |
| Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance. |
| Englinger B, Mair M, Miklos W, Pirker C, Mohr T, van Schoonhoven S, Lötsch D, Körner W, Ferk F, Knasmüller S, Heffeter P, Keppler BK, Grusch M, Berger W |
| British journal of cancer. 2017 Jan 17. pii: bjc2016449. doi: 10.1038/bjc.2016.449 |
| PMID: 28095394 |
| Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. |
| Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, Araki A, Brandstetter A, Mohr T, Hovestadt V, Chavez L, Kirchhofer D, Ricken G, Stefanits H, Korshunov A, Pfister SM, Dieckmann K, Azizi AA, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C |
| Neuro-oncology. 2017 Mar 24. pii: 3084538. doi: 10.1093/neuonc/nox027 |
| PMID: 28371821 |
| Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis. |
| Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, Hofmann T, Gerner C, Hermann G, Koellensperger G, Keppler BK, Berger W, Heffeter P |
| Cancer letters. 2017 Jul 14. pii: S0304-3835(17)30435-4. doi: 10.1016/j.canlet.2017.07.009 |
| PMID: 28716523 |
| FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. |
| Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M |
| Oncotarget. 2017 Sep 23. doi: 10.18632/oncotarget.21184. pii: 21184. pmc: PMC5675669 |
| PMID: 29152117 |
| 72 Einträge | 1, 2, 3, 4 › » |
Seite 1 / 4
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
